Avivagen Press Release Correction
THIS NEWS RELEASE IS INTENDED FOR DISTRIBUTION IN CANADA ONLY AND IS NOT INTENDED FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR DISSEMINATION IN THE UNITED STATES. Ottawa, ON/Business Wire/April 12, 2019/Avivagen Inc. (TSXV:VIV) (“Avivagen” or the “Company”), a life sciences innovation company with a series of patent protected products that support and optimize human …Read More
Avivagen Announces Results From Its Annual General Meeting April 10, 2019
Ottawa, ON / Business Wire / April 11, 2019 / – Avivagen Inc. (TSXV:VIV) (“Avivagen” or the “Corporation”), a life sciences corporation focused on developing and commercializing products for livestock, companion animal and human applications that, by safely supporting immune function, promote general health and performance, announces that at the Corporation’s Annual General Meeting (AGM) held …Read More
Avivagen Continues Expansion with an Order from a New Market in Asia
Ottawa, ON /Business Wire/ April 10, 2019 / – Avivagen Inc. (TSXV:VIV) (“Avivagen” or “Corporation”), a world leader in natural alternatives to antibiotics with its OxC-beta™ technology, is pleased to announce that it has received a new purchase order for its OxC-beta™ Livestock product. This order represents a new customer in a new jurisdiction and …Read More
Avivagen Announces Final Closing of Private Placement of Debentures and Shares
THIS NEWS RELEASE IS INTENDED FOR DISTRIBUTION IN CANADA ONLY AND IS NOT INTENDED FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR DISSEMINATION IN THE UNITED STATES. Ottawa, ON/Business Wire/April 9, 2019/Avivagen Inc. (TSXV:VIV) (“Avivagen” or the “Company”), a life sciences innovation company with a series of patent protected products that support and optimize human …Read More
Avivagen to Pursue Business Opportunities for Combining its Proprietary OxC-beta™ with Cannabis Products
Ottawa, ON / Business Wire/ April 3, 2019 / – Avivagen Inc. (TSXV:VIV) (“Avivagen”, or the “Corporation”) is pleased to announce that it has begun to explore the combination of Avivagen’s proprietary OxC-beta™ product with licensed cannabis products. Recently Avivagen has received inbound expressions of interest in exploring such product combinations from multiple, large integrated …Read More
Avivagen Announces Closing of Private Placement of Debentures and Shares
THIS NEWS RELEASE IS INTENDED FOR DISTRIBUTION IN CANADA ONLY AND IS NOT INTENDED FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR DISSEMINATION IN THE UNITED STATES. Ottawa, ON/Business Wire/March 28, 2019/Avivagen Inc. (TSXV:VIV) (“Avivagen” or the “Company”), a life sciences innovation company with a series of patent protected products that support and optimize human …Read More
